I.G. Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

I.G. Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-53,476	Closed	-$4.95M	–	442
2016 Q3	$4.95M	Buy	+53,476	New	+$5.04M	0.02%	382
2016 Q2	–	Sell	-23,050	Closed	-$1.9M	–	901
2016 Q1	$1.9M	Sell	23,050 -9,330	-29%	-$759K	0.01%	528
2015 Q4	$3.39M	Buy	32,380 +5,430	+20%	+$567K	0.01%	405
2015 Q3	$2.84M	Buy	26,950 +1,700	+7%	+$227K	0.01%	414
2015 Q2	$3.45M	Buy	25,250 +440	+2%	+$54.5K	0.01%	415
2015 Q1	$3.09M	Sell	24,810 -15,040	-38%	-$1.59M	0.01%	424
2014 Q4	$3.6M	Buy	39,850 +7,180	+22%	+$597K	0.01%	389
2014 Q3	$2.36M	Buy	32,670 +11,040	+51%	+$726K	0.01%	442
2014 Q2	$1.35M	Buy	21,630 +2,160	+11%	+$130K	﹤0.01%	558
2014 Q1	$1.33M	Buy	19,470 +3,980	+26%	+$293K	﹤0.01%	524
2013 Q4	$1.09M	Buy	+15,490	New	+$1.05M	﹤0.01%	555

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

I.G. Investment Management's BMRN Position: Q4 2016 in Review

I.G. Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 53,476 shares — an estimated $4.95M sold.

I.G. Investment Management first reported a position in BMRN in Q4 2013 and held it in 11 quarters. The position peaked at $4.95M in Q3 2016. 414 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

I.G. Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
I.G. Investment Management sold 53,476 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $4.95M.
I.G. Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 11 quarters.
I.G. Investment Management's BioMarin Pharmaceuticals position peaked at $4.95M in Q3 2016.
414 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on I.G. Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.